Patent foramen ovale & cryptogenic stroke
PFO and paradoxical embolism · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A patent foramen ovale is a common interatrial communication that can permit paradoxical embolism. In selected younger patients with cryptogenic stroke and a high-risk PFO, device closure reduces recurrent stroke compared with medical therapy alone.
Red flags
- Recurrent stroke despite therapy
- New atrial fibrillation detected on monitoring
- Evidence of deep vein thrombosis with PFO
- Large shunt with atrial septal aneurysm
- Stroke in an older patient (reconsider mechanism)
Assessment
Differential diagnosis
- Atrial septal defect
- Atherosclerotic/large-vessel stroke
- Small-vessel (lacunar) stroke
- Cardioembolic stroke from AF
- Dissection-related stroke
- Hypercoagulable-state embolism
Investigations
- Transthoracic/transoesophageal echo with bubble study (shunt, atrial septal aneurysm)
- Prolonged ambulatory ECG to exclude occult atrial fibrillation
- MRI brain to characterise infarct pattern
- Carotid/intracranial vascular imaging
- Thrombophilia screen in selected younger patients
- Lower-limb venous imaging if DVT suspected
Management
- Confirm the stroke is cryptogenic after thorough workup
- Exclude atrial fibrillation with prolonged rhythm monitoring
- Identify high-risk PFO features (large shunt, atrial septal aneurysm)
- Apply a validated causality assessment (e.g. RoPE score) in younger patients
- Discuss PFO closure in patients under ~60 with otherwise cryptogenic embolic stroke and high-risk PFO
- Proceed to percutaneous device closure in appropriate candidates
- Prescribe antiplatelet therapy after closure
- Use anticoagulation if a separate indication (e.g. DVT, thrombophilia) exists
- Avoid closure when another clear stroke mechanism is identified
- Counsel on the balance of recurrent stroke reduction versus new atrial fibrillation risk
- Coordinate neurology and cardiology shared decision-making
- Arrange echo follow-up for residual shunt
Drugs & doses
Aspirin 75-100 mg PO OD (antiplatelet after closure or medical therapy)
Clopidogrel 75 mg PO OD (added short-term after device, or alternative)
Apixaban 5 mg PO BD if a separate anticoagulation indication exists
No routine anticoagulation for isolated PFO without another indication
Disposition
Joint neurology and cardiology (ACHD/structural) decision; device closure in selected patients with specialist follow-up.
Complications & pitfalls
- Recurrent paradoxical embolism
- New-onset atrial fibrillation after device closure
- Device-related thrombus or erosion
- Residual shunt
- Bleeding from antithrombotic therapy
Exam pearls
- PFO closure benefits are clearest in patients under 60 with high-risk anatomy and no competing stroke cause
- Device closure carries a small risk of new atrial fibrillation — usually transient
- A right-to-left shunt on bubble study supports a paradoxical mechanism
- Closure is not indicated for incidental PFO without embolic events
- Exclude occult AF before attributing stroke to a PFO
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.